Skip to content

Evaluation of the clinical efficacy of traditional Chinese medicine in the treatment of children's acute respiratory infectious diseases --Clinical Study on Children Chai Fang Jie Du Granule in Treating influenza in Children

Evaluation of the clinical efficacy of traditional Chinese medicine in the treatment of children's acute respiratory infectious diseases --Clinical Study on Children Chai Fang Jie Du Granule in Treating influenza in Children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113852
Enrollment
Unknown
Registered
2025-12-03
Start date
2024-01-03
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Control group:Oral oseltamivir phosphate capsules+Chinese herbal placebo granules
Treatment group:Oral administration of Children Chai Fang Jie Du Granule+Oseltamivir phosphate capsules

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Conform to the diagnostic criteria of influenza, wind heat invading the lung syndrome in TCM; 2. The course of the disease is less than 48 hours without relevant treatment; 3. Age range from 3 to 16 years old; 4. No concomitant systemic lesions; 5. Sign an informed consent form and be willing to cooperate with examinations and treatments.

Exclusion criteria

Exclusion criteria: 1. The course of the disease is >= 48 hours, or other symptomatic treatments have been received; 2. Exclude diseases that need to be distinguished from influenza, such as pharyngeal conjunctival fever, herpetic pharyngitis, measles, childhood rash, acute pharyngitis, purulent tonsillitis, and other respiratory infections and infectious diseases; 3. Children with organic lesions; Children with other serious diseases such as cardiovascular, liver, kidney, and hematopoietic systems; Children with a history of febrile seizures, etc; 4. Severe influenza, urgent need for supportive treatment, etc; 5. Allergy to the investigational drug or serious adverse reactions.

Design outcomes

Primary

MeasureTime frame
Clinical comprehensive efficacy;

Secondary

MeasureTime frame
antipyretic time;Traditional Chinese Medicine Syndrome Points;Virus antigen conversion rate;

Countries

China

Contacts

Public ContactBo Wang

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

2323828611@qq.com+86 139 1196 5762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026